Key facts
- Ignite Biomedical’s last known valuation is $116.0M (Dec 2024).
- It has raised $9.2M; the latest was Equity Crowdfunding ($170K) in Jul 2025.
- Status: Privately Held (backing).
- ·Watchlist + deal alerts for Ignite Biomedical
- ·The full record, as it builds
Funding rounds
No funding rounds for Ignite Biomedical are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Ignite Biomedical
Developer of medical solutions designed to deliver transformative advancements in medical science. The company offers a Therapeutic Response Predictor Blood Test solution that allows the objective prediction of drug response before initiating therapy, using a rapid discovery-to-test development process, also provides biomarker tests with high sensitivity and leverages AI-based technology to solve complex issues across all disease states, enabling physicians to prescribe the right drug for their patients.
- Sector
- Healthcare
- HQ
- Framingham, MA, United States
- Founded
- 2022
- Employees
- 6
- Website
- ignitebiomedical.com/
- Ownership
- Privately Held (backing)
Ignite Biomedical doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Ignite Biomedical shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Ignite Biomedical in its N-PORT filings yet. We sweep new filings monthly.